Theriva Biologics
TOVX
26 hedge funds and large institutions have $34.2M invested in Theriva Biologics in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
3% more capital invested
Capital invested by funds: $33.1M → $34.2M (+$1.06M)
0% more funds holding
Funds holding: 26 → 26 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$293K |
| 2 |
RFC
Regions Financial Corp
Birmingham,
Alabama
|
+$179K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$81.3K |
| 4 |
M&T Bank
Buffalo,
New York
|
+$65K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$65K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$345K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$180K |
| 3 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
-$43K |
| 4 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$41K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$32.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BIM
26
BlackRock Investment Management
Wilmington,
Delaware
| $14K | – | – | – |
|
27
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $5K | – | – | – |
|
28
Creative Planning
Overland Park,
Kansas
| $4K | – | – | – |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $4K | – | – | – |
|
30
Wells Fargo
San Francisco,
California
| $2K | – | – | – |
|
|
TC
31
TFS Capital
West Chester,
Pennsylvania
| – | -$345K | -23 | Closed |
|
|
ARTA
32
A.R.T. Advisors
New York
| – | -$180K | -12 | Closed |
|
|
BGA
33
Belmont Global Advisors
Dallas,
Texas
| – | -$43K | -3 | Closed |
|
|
HLA
34
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
| – | -$41K | -3 | Closed |
|
|
GC
35
Guggenheim Capital
Chicago,
Illinois
| – | -$25K | -2 | Closed |
|
36
BNP Paribas Financial Markets
Paris,
France
| – | -$1.9K | – | – |
|
|
GT
37
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$4K | – | – |
|
|
GSC
38
Ground Swell Capital
Folly Beach,
South Carolina
| – | -$1K | – | – |
|
|
U
39
UBS
Zurich,
Switzerland
| – | -$6K | – | – |
|
TOVX Hedge Fund Activity: Q3 2014 in Review
26 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2014, worth a combined $34.2M — up 3.2% from $33.1M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TOVX positions and 5 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $293K. The largest seller was TFS Capital, exiting entirely with an estimated $345K sold.
- 26 institutional investors held Theriva Biologics (TOVX) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $34.2M of Theriva Biologics stock for Q3 2014, up 3.2% quarter-over-quarter.
- 6 funds opened new Theriva Biologics positions in Q3 2014 and 5 closed out, a net change of +1 holder.
- The largest Theriva Biologics buyer in Q3 2014 was Vanguard Group, an estimated $293K added.
- The largest Theriva Biologics seller in Q3 2014 was TFS Capital, an estimated $345K sold.
Based on aggregated 13F filings for Q3 2014.